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Peptide-based approaches to mimicking protein inter-
active regions have relied mainly on linear peptides;
however, most binding sites are discontinuous and
thus not easily reproducible by a linear sequence.
Any attempt to replicate those sites by chemical
means must not only integrate all residues involved
in the recognition but also provide structural organiza-
tion to native-like levels. Here we describe a surface
mimic approach to the reconstruction of such com-
plex molecular architectures, using as a model a dis-
continuous antigenic site of foot-and-mouth disease
virus that is defined by residues belonging to three
different capsid proteins. Our surface mimics are syn-
thetic cyclic peptides, designed in silico, capable of
binding antibodies directed to this site, and with dem-
onstrated functional capabilities as vaccines in guinea
pigs. Further, by saturation transfer difference NMR,
we have determined several antibody binding resi-
dues on these peptides.
Introduction
Protein-protein interactions play a fundamental role in
events such as cell communication and division, signal
transduction, protein degradation, and all types of regu-
latory mechanisms [1]. These interactions are essential
in the formation of multiprotein complexes that integrate
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ganelle structures. They are equally crucial in the cellular
responses to foreign agents such as those that rely on
antigen-antibody recognition.
In characterizing these molecular events, it is not
enough to define the interacting partners for a given pro-
tein but also how the interaction takes place, that is, the
identity and structural orientation of the residues actu-
ally involved, in order to design replicas of the binding
sites or drugs disturbing the interaction [2]. A minimalist
approach to these molecular recognition processes has
focused on the interacting protein surfaces. The specific
properties of those interfaces, such as predominant
interaction types or amino acid composition, are partic-
ularly relevant. While the interface core is often charac-
terized by a high content of hydrophobic and aromatic
residues, the surrounding rim remains accessible to
solvent after complex formation and must also be con-
sidered part of the interaction patch [3]. With these
assumptions, constructions appropriately mimicking
these contact surfaces can be used as protein-protein
interaction models as well as simplified but functional
replicas of proteins. Peptides are particularly advanta-
geous in this respect, given their synthetic availability,
relative flexibility, and high solvent accessibility of
most of their structure.
One widely studied example of molecular recognition
processes is antigen-antibody interaction. Peptides de-
signed as replicas of antigenic sites of several patho-
gens have been widely exploited in the development of
chemically defined synthetic vaccines [4]. Despite their
occasionally lower immunogenicity, peptide-based vac-
cine approaches, or other strategies involving a simpli-
fied rebuilding of the target antigen such as plasmid
DNA, recombinant protein subunits, or empty capsids,
offer demonstrable advantages over conventional vac-
cines, especially with regard to safety, storage, and
standardization.
The reproduction of antigenic sites by chemical
means involves different degrees of difficulty depending
on the level of discontinuity of the interacting residues in
the protein backbone. Protein folding and viral subunit
assembly bring sequence-distant residues into close
spatial proximity, which in practice means that few anti-
genic sites can be easily simulated by linear peptides re-
producing consecutive residues of a single antigenic
protein. Reconstruction of those discontinuous protein
binding sites is a major goal in molecular engineering.
Much of its challenge lies in building up chemical groups
so that a native-like orientation of the critical interacting
residues can be achieved. The complexity of this task is
the main reason for the low success rate in such at-
tempts and therefore the few examples existing in the
literature [5, 6].
Previous peptide approaches to this problem have
been based on grafting together two or more peptide
fragments containing residues defining the epitope [7].
Our group used this approach to mimic a discontinuous
antigenic site on the capsid of foot-and-mouth disease
virus (FMDV) [8]. Five key amino acids located in three
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(monoclonal antibody resistant) mutant analysis [9] as
defining the antigenic site D. These three fragments
were spliced in a single peptide construction, designed
on structural criteria, that was able to induce moderate
levels of neutralizing antibodies [10], an important re-
quirement for a vaccine candidate [11].
In the present work we have explored a completely
different strategy, switching from the concept of loop in-
tegration to that of reproducing the composition of the
critical interface amino acids, by developing a surface
mimic approach to the discontinuous antigenic site of
FMDV. We believe that similar design criteria could be
applied to the chemical reconstruction of other discon-
tinuous binding sites.
Results
Surface Mimic Peptide Design by Rational Assembly
of Exposed Native Fragments
A previous prototype of antigenic site D mimic was de-
signed [10] by assembling into a single molecular entity
the three loops (one each from VP1, VP2, and VP3) con-
taining site D residues. Connections among the loops
involved residues at the inner capsid region in order to
minimally perturb the environment of the interacting
residues (see Figures 1D–1F for more details).
In designing our new surface mimic peptide of anti-
genic site D, we have taken a complementary but con-
ceptually alternative approach to the one described
above. First, the new design includes some additional
structural elements, such as the most exposed part of
the VP2 (130–141) loop. Three lines of evidence led us
to favor including this loop as a likely (yet so far unre-
ported) constituent of discontinuous site D: (1) excellent
accessibility and central location in the midst of the
three loops previously considered; (2) preliminary data
proving a positive recognition between peptides includ-
ing this VP2 (130–141) region and site D antibodies; and
(3) the fact that the same loop is a constitutive element of
an antigenic site in another FMDV serotype.
Second, in order to preserve as much as possible the
physical properties of the recognition interface, its
amino acid composition has been maintained, that is,
surface-exposed residues, not defined as antigenically
critical by mutational studies but comprised in the
same region, have also been considered in the design.
Third, peptide sections located inside the capsid have
been trimmed off, and thus only selected segments con-
taining surface-exposed, interfacial residues have been
incorporated. Overall, while in the design of our earlier
D8 construct [10] we adopted a ‘‘cross-sectional view’’
(Figure 1D) of the capsid, the present surface mimic
approach views the capsid ‘‘from the front’’ (Figure 1A)
and deals only with highly exposed elements.
In silico dissection of an approximately 253 25 A˚2 sur-
face area, delimited by the five residues originally defin-
ing site D (T193 from VP1, S72, N74, and H79 from VP2
and E58 from VP3), provides as candidate components
of a surface mimic four protein loops (VP1 [191–195],
VP2 [72–79], VP3 [58–61], and VP2 [132–137]) plus four
individual amino acids (P186 [VP2] and Y63, K84, and
N88 [VP3]). As shown in Figure 1B, all these elements
in the virus can be viewed as adopting a quasicircularlayout. A first prototype, the cD1 cyclic peptide, was
thus designed with a view to integrating most of the
above elements while accomplishing a pseudocyclic,
native-like outline. On these premises, the final viral ele-
ments included in cD1 were, from the N to C terminus:
VP1 (193–195), VP3 (84), VP3 (58–60), VP3 (63), VP2 (72–
80), and VP2 (133–137), with intentional sequence reor-
ganization of the latter (SEKDR instead of SDREK) due
to better structural fit (Figure 1C). The gap between the
two most remote residues in the capsid (T193 [VP1]
and K135 [VP2]) was bridged by two disulfide-bonded
Cys residues, imposing a certain degree of conforma-
tional restriction on the construct, and by a Gly residue,
providing some compensatory flexibility. This design
resulted in the sequence CTGDKENVYPSQNFGHMHK
SEKDRGC, shorter and synthetically simpler, thus better
suited than the D8 heterodimer as a vaccine candidate.
cD1 Peptide Synthesis
The linear precursor of cD1, cD1L, with Cys residues at
both ends, was prepared by solid phase Fmoc-based
methods. After cleavage, deprotection, and purification,
oxidation at high dilution and basic pH led to cyclic cD1.
Three different oxidation conditions ([1] GSSG-GSH re-
dox pair under N2, room temperature, [2] same at 5
C,
and [3] air oxidation, room temperature) were monitored
on a small scale by HPLC, Ellman’s test, and MALDI-TOF
MS. After 4 hr, cyclizations under inert atmosphere were
not completed and a byproduct corresponding to Met
oxidation was detected. MS analysis also showed
traces of a glutathione-cD1L heterodimeric disulfide.
For all of these reasons, method 3 was chosen for
large-scale cyclization. Further details are provided in
the Supplemental Data available with this article online.
cD1 Peptide-Site D Antibody Interaction
Studies by ELISA
The cD1 surface mimic peptide and its linear precursor
cD1L were both assayed by ELISA for binding to several
monoclonal and polyclonal antibodies directed to the
antigenic site D region (Figure 2). A positive control
with virus particles is also shown. Given the high speci-
ficity of these antibodies, originally generated against
the native discontinuous epitope [12], this is quite a de-
manding test of the structural mimicry achieved by the
synthetic constructs vis-a`-vis the highly ordered virus
epitope. In fact, no previous design of site D mimics
has been successful by this stringent criterion [10], de-
spite their ability to induce neutralizing antibodies. In
the present case, however, both cD1 and cD1L peptides
were recognized by the antibodies (Figure 2). Therefore,
compared with our previous D8 prototype, cD1 appears
to be a better design in terms of native site D mimicry.
Whereas the polyclonal antibodies showed superior
affinity for cD1 and cD1L, probably due to their higher di-
versity, monoclonal antibodies were also able to bind
both peptides, in the order 5C4 > 2E5 > 3E9 > 2A12.
On the basis of the mutational studies used to define
site D [9], our results indicate that the novel design re-
produces especially well the VP2 (72–79) region of the
virus, and to a lesser extent the VP1 component (T193
region). Interestingly, neither of the two peptides was
recognized by either SD6, a monoclonal antibody di-
rected to antigenic site A of the FMDV, nor by polyclonal
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817Figure 1. Dissection of a Surface Binding Patch
Design process of a surface mimic peptide (A–C) representing discontinuous antigenic site D of FMDV and comparison to a previous construc-
tion, D8 (D–F).
(A) Front view of the antigenic site D of FMDV. The five amino acids defining the site are displayed in CPK models and constitute the limits for
the elements to be included in the design. Surface most-exposed fragments comprised in those boundaries are colored in white. The novel
loop included in this design (VP2 [132–137]) contains a highly exposed Arg, a candidate to interact with antibodies (see text) and also repre-
sented in CPK.
(B) The elements defined in (A), including four peptide fragments and several isolated amino acids from all three structural proteins, can be
viewed as defining a cycle, represented by a purple arrow.
(C) Incorporation of surface viral elements into a 26 residue peptide (amino acids in single letter code), which from N to C terminus reproduces
VP1 (193–195, TGD), VP3 (K84), VP3 (58–60, ENV), VP3 (Y63), VP2 (72–80, PSQNFGHMHK), and VP2 (133–137, SEKDR, slightly reorganized
from native SDREK for structural reasons). The quasicircular structure is closed by a disulfide bond between two nonnative Cys residues
inserted at the ends of the arrow and a Gly at the C terminus.
(D) Cross-sectional view of the antigenic site D of FMDV, representing elements included in the previous design, D8. Antigenically relevant
fragments were connected via a polyproline module and a disulfide bond (shown in white), all involving residues at the inner side of the capsid.
(E) Front view of the fragments included in D8 and their assembly, as compared to cD1 (B).
(F) In the D8 heterodimer, VP2 and VP3 fragments, located antiparallel to each other, were joined into a single 32 residue peptide chain by
means of a polyproline (n = 8) linker, assuming that the relatively rigid poly-Pro II helix accurately spanned the gap between both ends. An
additional 7 residue fragment, representing VP1, was connected to VP3 by a disulfide bond. Nonnative elements are displayed in purple.sera elicited against a linear peptide reproducing site A
(A24), thus confirming the specificity for site D anti-
bodies. Somewhat unexpectedly, better recognition
was observed for the linear cD1L peptide, suggesting
that the cyclic cD1 version imposes too tight a confor-
mational constraint that prevents optimal fitting. To ad-
dress this latter point we optimized the cD1 design, in
order to achieve more flexible constructions.
Exploration of Flexible Versions of cD1 Peptide
The major structural restriction introduced in cD1 design
is the nonnative disulfide bridge. In addition to the re-
duction in mobility inherent to any cyclic structure, disul-
fide dihedral (Cb-S-S-Cb) angles are usually confined to
values of 90 or290 and contribute an extra conforma-
tional constraint. Previous studies with cyclic disulfides
[13] mimicking the GH loop of VP1, which defines the
continuous antigenic site A of FMDV, had suggested
that the introduction of u-amino acids next to either of
the cysteines of the disulfide bond increased to some
degree the flexibility of the cycle and therefore provided
more possibilities for conformational exploration, even-tually converging onto the native epitope structure. In
line with this, we extended this approach to our search
for cyclic surface mimics of the discontinuous D epi-
tope, and thus designed three novel constructions
Figure 2. cD1 Peptide Recognition by Monoclonal and Polyclonal
Site D Antibodies
Peptide-antibody binding evaluated by direct ELISA between cyclic
peptide cD1 (filled bars), its linear precursor cD1L (diagonally lined
bars), native virus (open bars), or heterodimeric design D8 (horizon-
tally lined bars) and site D monoclonal (2A12, 2E5, 3E9, 5C4) and
polyclonal (gp2, gp3, gp4, gp5) antibodies. Controls with antibodies
to site A (monoclonal SD6 and polyclonal A24) are also shown.
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818with u-amino acids at either side of the disulfide bridge
(Figure 3A), synthesized using the same chemistry as
that for cD1. These three peptides, cD2, cD3, and cD4,
as well as their linear precursors, cD2L, cD3L, and
cD4L, were assayed for interactions with monoclonal
and polyclonal antibodies spanning discontinuous site
D, as previously done for cD1L and cD1. As expected,
all linear peptides showed similar antibody reactivities
(Figure 3B). Cyclization had a negative effect on the
recognition of peptides cD3 and cD4. Peptide cD2,
however, was superior to its linear precursor, evidenc-
ing appropriate structural organization for antibody
binding. In this particular case, the required flexibility
was achieved by a 6-aminohexanoic acid (Ahx) residue
inserted next to the C-terminal Cys, while the intramo-
lecular disulfide maintained the optimal conformation
for recognition.
Figure 3. Flexible Cyclic Analog Sequences and Antibody Recogni-
tion
(A) Sequences of peptides cD2, cD3, and cD4, proposed as flexible
analogs of the surface mimic cD1. For each peptide, residues intro-
duced at positions Z and/or X are indicated.
(B) Recognition by site D antibodies of cyclic peptides (filled bars)
cD2, cD3, and cD4 and their linear precursors (diagonally lined
bars) cD2L, cD3L, and cD4L. Monoclonal and polyclonal antibodies
are shown, including controls with site A monoclonal SD6 and anti-
sera to peptide A24, representative of continuous site A.In Vivo Evaluation of Peptides
as Vaccine Candidates
All four cyclic peptides were taken one step further and
assayed as vaccine candidates, by testing in vivo for
their ability to elicit neutralizing antibodies and eventu-
ally generate in an animal model a protective immune
response against viral infection.
For each of the cyclic peptides and controls, guinea
pigs 1–16 were inoculated and boosted 21 and 42 days
after immunization. Controls included the site D mimic
D8 (17) from previous designs [10], a conventional
FMDV vaccine based on inactivated virus (21, 22), and
antigen-free animals (19, 20). Sera were collected at
days 0 and 63. All four cyclic disulfides were highly immu-
nogenic when formulated as free peptides without conju-
gation to a carrier protein, giving rise to high antibody ti-
ters (around 5 by direct ELISA against the corresponding
peptide antigen) in the same order of magnitude as for
the D8 control (titer defined as the logarithm of the dilu-
tion giving a 3-fold absorbance value over the blank).
Titers for vaccinated animals with inactivated virus were
only slightly higher (around 6). These data are presented
in the Supplemental Data. The improved recognition may
relate not only to the length (26 residues) and intrinsic im-
munogenicity of the sequences but also to the resistance
to degradation provided by the cyclic structures [14].
This primary level of immunogenicity, however, must
be validated by the more demanding requirement of
specificity toward the native antigen, if the synthetic pep-
tide is to be of any use as a vaccine candidate.
Viral neutralization assays where reduction of FMDV
infectivity was measured were performed in cell culture
by combining serial serum dilutions with infectious virus
and then incubating baby hamster kidney (BHK) cells
with the mixtures. As shown in Figure 4, for peptides
cD1 and cD2 (the latter with a flexible Ahx acid residue
close to the C terminus), a substantial reduction in viral
infective capacity was obtained at high serum (i.e., anti-
body) concentration. In contrast, for peptides cD3 and
cD4, where the flexible Ahx unit is at the N-terminal
side, the reduction in infectivity was much lower. Control
sera from animals vaccinated with inactivated virus
showed 100% neutralization at the dilutions assayed.
Negative results with PBS controls are also shown. Fi-
nally, comparisons of cD1 and cD2 antibodies with D8
antisera, in terms of viral infectivity reduction, also favor
thenewsurfacemimic peptidesover theprevious design.
A final requirement, prior to evaluating the present sur-
face mimic peptides as vaccines in FMDV natural hosts,
was testing them for in vivo protection of immunized
guinea pigs directly exposed to FMDV virus. Three weeks
after the second boost, animals were challenged with 106
plate-forming units (PFU) of a guinea pig-adapted FMDV
[15] and monitored for 6 days for appearance of lesions
on the inoculation site (primary lesions) and the other
paws and tongue (secondary lesions). The time course
of emergence of primary and secondary lesions upon
guinea pig challenge with a guinea pig-adapted strain
of FMDV usually shows animal-to-animal variation [16],
and minor, transient primary lesions at the inoculation
point can be observed in conventionally vaccinated
animals. Thus, the criteria for full protection are based
on the absence of lesions at day 6 postchallenge. As
shown in Table 1, vaccination with peptides cD3 and
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protected and severe primary and secondary lesions
were detected. One out of three animals immunized
with cD2 was fully protected, as judged by the absence
of lesions in locations other than the inoculation site,
and a second one showed minor lesions only. In the
cD1 group, one animal developed a single minute lesion.
Poor statistics for D8 in these experiments are com-
pensated by previously published neutralization results
with D8 peptide [8] and D8 analogs D2, D4, D7, and D10
[10]. All in all, evidence from the neutralization experi-
ments suggests that the surface mimic is also superior
in vivo to the D8 construct.
Peptide-Antibody Interaction and Epitope
Mapping by STD-NMR
ELISA is the preferred method to study antigen-antibody
interactions, mainly due to its throughput capabilities
and sensitivity. However, structural conclusions are dif-
ficult to draw on the basis of these experiments alone,
and the expected structural bias induced by antigen
immobilization on the ELISA plate advises against it.
Therefore, we decided to perform a series of NMR
experiments in order to identify the structural features
that allow cDn peptides to bind site D antibodies. This
seems an appropriate technique in that it not only can
afford structural information with atomic resolution but
also because it does so in a solution environment.
Figure 4. Antipeptide Antibodies Reduce Viral Infectivity in Cells
Viral infectivity reduction in cell culture by sera from guinea pigs im-
munized with peptides cD1, cD2, cD3, or cD4, extracted 3 weeks
after the third inoculation. Controls with preimmune sera revealed
neutralization levels below 3%.Peptide-antibody systems are difficult to study by
NMR with the most common interaction experiments
[17, 18], primarily due to antibody production limitations
either amount-wise or in terms of isotopic enrichment,
but also as a consequence of the large size of the pep-
tide-antibody complex. Nevertheless, recent develop-
ments in the NMR field provide a set of experiments
that require amenable amounts of antibody and no isoto-
pic enrichment [19]. These techniques have no molecular
weight limitation [20] because they rely on the observa-
tion of the ligand (in our case the peptide), and are capa-
ble of extracting structural information on its bound
state. Among several studies using NMR to characterize
peptide-antibody recognition [21], saturation transfer
difference (STD) experiments are the most widely em-
ployed [22]. They consist of the observation of saturation
transferred from the protein to the ligand (antibody and
peptide, respectively) in the complex. The transfer im-
plies complex formation but also provides information
on the mode of ligand binding, thus allowing binding-
epitope delineation. However, due to intrinsic limitations
of these experiments, binding must occur in the fast ex-
change regime, which means binders with dissociation
constants in the mM range. Our ELISA results suggest
that the binding affinity between anti-site D antibodies
(monoclonal and polyclonal) and cDn peptides might
be in the appropriate range for STD experiments.
With a view to obtaining a full exploration of the anti-
genic site, we chose to use the wide antibody repertoire
provided by the polyclonal sera fraction directed to
the discontinuous native epitope. Our approach is some-
how the reverse of more usual STD experiments, in
the sense that in the present case the combinatorial
element is supplied by the protein partner (a mixture of
antibodies) instead of the ligand (single peptide),
Table 1. Protection against Foot-and-Mouth Disease in Guinea





cD1 1 3 3 2 2 0 3 3 2 2 0
2 2 2 1 0 0 1 1 3 3 0
3 2 1 0 0 0 2 1 0 0 0
4 0 0 0 0 0 0 0 0 1 0
cD2 5 0 0 0 0 0 2 2 0 0 0
7 1 0 0 0 0 0 0 0 0 0
8 4 4 0 2 0 4 4 2 1 0
cD3 9 2 2 0 0 0 3 3 0 1 0
10 2 2 0 1 0 2 2 0 0 0
12 2 3 0 3 0 3 3 1 3 0
cD4 13 0 1 0 2 0 0 2 0 3 0
14 2 2 0 0 0 3 3 0 1 0
15 0 3 0 0 0 0 3 0 1 0
16 2 3 1 1 0 2 2 0 2 0
D8 17 2 2 1 0 0 3 1 2 2 0
None 19 0 1 0 0 0 1 1 1 0 0
20 0 0 0 1 0 1 2 2 2 0
Vaccine 21 1 0 0 0 0 0 0 0 0 0
22 0 0 0 0 0 0 0 0 0 0
a The clinical score used to evaluate severity of lesions ranged from
0 to 4 (0, no lesion; 4, serious lesion) in the four paws, and from 0 to 2
in the tongue. For each animal the five digits refer, respectively, to
rear left paw (inoculation site), rear right paw, front left paw, front
right paw, and tongue.
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tion of the peptide residues interacting with any site D
antibody. The peptide of choice was cD2, the one pro-
viding the best antibody response.
A number of transients and irradiation frequencies
were explored, with 8000 scans selected as a good com-
promise between signal-to-noise ratio and experiment
length, and d 21 ppm as the most efficient frequency.
Control experiments were also performed, showing
that internal subtraction during the experiments was de-
void of artifacts, and that nonantibody-mediated pep-
tide saturation was also inexistent at the chosen irradia-
tion frequency (Figure 5A).
The large number of scans required can be explained
by either weak binding or by the peptide interacting with
only a small fraction of the polyclonal antibody popu-
lation, a fact easily rationalized in the context of the
heterogeneous and diverse population of antibodies
present in the sample. In our case, the observation of
signals in the aliphatic, aromatic, and amide regions of
the peptide spectrum clearly implied that recognition
between cD2 and site D antibodies was taking place,
as seen by ELISA.
Figure 5. STD-NMR Experiments to Evaluate Binding of cD2 Pep-
tide and Heterogeneous Mixture of Antibodies from Polyclonal Se-
rum gp5
Amide region for experiments:
(A) STD experiment for cD2 peptide in the presence of serum.
(B) 1H-NMR spectrum.
(C) Control STD experiment with a sample containing cD2 peptide
in the absence of serum.
(D) Subtraction control using the same on- and off-resonance fre-
quencies.
(E) cD2 sequence, where X stands for 6-aminohexanoic acid. Those
epitope residues involved in the interaction with antibodies accord-
ing to STD-NMR are highlighted in yellow; antigenically critical res-
idues identified by mutational experiments [9] are in blue; residues
selected by both methods are shown in green.One outstanding feature of STD experiments is that
they allow locating the epitopes responsible for interac-
tion on the ligand site [21, 23]. Standard 2D TOCSY and
NOESY experiments [24] allowed full assignment of pep-
tide resonances (Table S3), which in turn were used to
identify the STD signals corresponding to amino acids
in close contact with the antibody in the complex. De-
spite some overlap in the amide region of the STD exper-
iment (Figure 5A), Tyr9 HN and side chain resonances,
together with other signals from Phe14, His16, and
His18 side chains, could be assigned, altogether defin-
ing a hydrophobic binding core that might be easily
affected by mutations at adjacent positions.
Besides, NOESY experiments also showed that addi-
tion of site D antibodies did not produce significant
changes in cD2, neither in terms of nuclear Overhauser
effect (NOE) signal (negative, as corresponds to a pep-
tide of the size of cD2) nor in the number of NOESY
crosspeaks. The lack of intense transferred NOEs medi-
ated by complex formation agrees with the observation
of a weak cross-saturation effect in the STD experiment,
and again this is probably due to antibody heterogeneity
and the limited fraction of the peptide associating with
antibodies.
Discussion
The structural complexity inherent to discontinuous
binding sitesmakes their replicationan extremelydifficult
and challenging task [7]. The particular example studied
here deals with antigen-antibody recognition and how
peptide replicas can be used as synthetic vaccines.
In those cases where recognition can be achieved by
a partial representation of the epitope, extensive screen-
ing of peptide libraries for antibody binding serves as
a first step to find low-affinity linear segments that can
be combined into a higher affinity ligand [6]. However,
in most cases, such as the FMDV site D presented here,
this approach is not applicable because none of the
integrating components of the antigenic site is, by itself,
able to recognize antibodies elicited against the virus,
nor capable of inducing the production of virus binding
antibodies [10].
A possible solution to this problem is to assemble into
a single molecule the main components involved in the
recognition event, as done in our earlier, partially suc-
cessful construct [10]. We now show that integrating
all surface-exposed residues comprised in the bind-
ing area, including parts of the earlier construct [10],
achieves a much better functional mimicry of the epi-
tope. Further consideration of the structural features of
the fragments to be included in the new construct sug-
gested a cyclic peptide in a crown-like shape as the
choice. Insertion of flexible u-amino acids at appropri-
ate positions provided a precise regulation of the subtle
balance between rigidity and flexibility essential for
optimal antibody binding.
The exceptional finding of a peptide construction able
to bind antibodies generated against a discontinuous
epitope encouraged us to examine the binding in solu-
tion, in order to describe for the first time how the inter-
action takes place, that is, which residues are directly
exposed to the antibody contact. Because cyclic pep-
tide cD2 interacted best with site D antibodies, we
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rate definition of the antigenic site. Epitope mapping by
STD-NMR suggests key involvement of aromatic resi-
dues Tyr9, Phe14, His16, and His18 in the cD2 interac-
tion with site D antibodies. This network of aromatic
amino acids encompasses a series of residues (Ser11,
Asn13, and His18 in our designed cD2 peptide, corre-
sponding to Ser72, Asn74, and His79 of the VP2 capsid
protein) that have been described as crucial for antigen
recognition by site D antibodies, because they tend to
undergo mutations under immune pressure [9].
The residues observed in the STD experiment would
seem to provide a set of hydrophobic interactions, and
consequently important surface burial, to allow the
flanking residues (Ser11, Asn13, and His18) the forma-
tion of a hydrogen bond network. Prevalence of aro-
matic resonances in the STD experiments can be under-
stood by the nature of hydrophobic interactions, which
generally places ligand atoms closer to the receptor
where saturation transfer is more efficient. Biased inter-
actions to the VP2 (72–79) fragment were also observed
by ELISA, where monoclonal antibodies 5C4 and 2E5
were the best peptide binders. However, appropriate
structural disposition of those residues for productive
binding is uniquely achieved by the surface mimic de-
sign, as neither individual peptide fragments comprising
VP1 (189–194), VP2 (71–84), and VP3 (52–62) nor the ear-
lier D8 construct were able to interact with site D anti-
bodies [10].
Effective peptide-antibody recognition was comple-
mented by an even more relevant functional feature:
when assayed on guinea pigs, synthetic cD2 showed
vaccine capabilities at three levels: (1) it elicited anti-
bodies that recognized and (2) neutralized FMDV, and
(3) it afforded partial but significant protection of the
animals against FMDV challenge.
In sum, superiority of cD2 over the previous D8 con-
struct arises not only from synthetic and structural sim-
plicity (a simple 26 residue peptide ring versus a hetero-
dimer of 32 + 7 amino acids) but more importantly from
the fact that our new surface mimic constructions are
uniquely able to recognize site D antibodies. In addition,
neutralization levels of anti-cD2 antibodies are higher
than those reported for anti-D8 sera [8].
It has been previously proposed that an ideal FMDV
synthetic vaccine must be based on a multiepitope pep-
tide cocktail representing major antigenic sites [25, 26].
Adding site D constructions such as D8 to conventional
site A peptides has been shown to induce a more pro-
miscuous and better neutralizing antibody repertory, in-
cluding T cell response to site D [25]. Such a double epi-
tope combination can be effective in overcoming the
challenge posed by highly mutable RNA viruses such
as FMDV. Peptide cD2, the best site D peptide replica
to date, is thus an obvious candidate for a multicompo-
nent synthetic vaccine. Further, the surface mimic ap-
proach used here for FMDV site D can be appropriately
extended to other discontinuous binding sites that play
key roles in the vast majority of interaction events.
Significance
Although continuous antigenic sites have been classi-
cally reproduced by linear peptide sequences, mostantigenic sites and other binding regions of proteins
are composed of sequence-wise remote elements
and thus cataloged as discontinuous. Their integra-
tion into a molecule available by chemical means is
a tall order in molecular engineering and has to con-
sider structural as well as chemical features.
In this work, a surface mimic approach has been
proven superior to other chemically built discontinu-
ous protein binding sites, such as an earlier construc-
tion where several loop fragments were assembled.
For the first time, the discontinuous antigenic site D
from FMDV, constituted by fragments from three dif-
ferent proteins, was replicated by a single peptide
able to bind viral monoclonal antibodies. The interac-
tion was characterized by STD-NMR, and key peptide
residues directly involved in antibody recognition
were identified. These amino acids, mainly aromatic
in nature, are at most two positions away from those
residues defining site D by mutational analysis, sug-
gesting that such mutations would alter the conforma-
tion of the hydrophobic contact pattern on the viral
surface and thus allow the virus to escape antibody
recognition.
The designed cyclic peptides, with variable levels of
rigidity, were not only evaluated for antibody binding
but also functionally assayed as vaccines on a guinea
pig model. Modulation of flexibility dramatically af-
fected the antibody recognition and general activity,
with the candidate having an u-amino acid inserted
next to the C-terminal end showing better protection
against viral infectivity both in vivo and in vitro. This
peptide will be used in future synthetic FMDV vaccine
candidates. The surface mimic approach hereby cho-
sen can be viewed as a general strategy for recon-




Protected Fmoc amino acids were purchased from Novabiochem
(Strasbourg, France) and Bachem (Bubendorf, Switzerland). Rink
amide p-methylbenzhydrylamine resin (0.73 mmol/g) was from No-
vabiochem. Anisole, thioanisole, ethanedithiol (EDT), piperidine,
and N,N0-diisopropylcarbodiimide were from Sigma-Aldrich-Fluka
(Madrid, Spain). Peptide synthesis-grade dichloromethane (DCM),
dimethylformamide (DMF), and HPLC-grade acetonitrile were from
SDS (Barcelona, Spain).
Preparative HPLC separations were done on a Phenomenex Luna
C8 reverse-phase column (21.2 3 250 mm, 10 mm particle size) on
a Shimadzu SCL-10A system. Analytical HPLC runs were performed
on a Phenomenex Luna C8 reverse-phase column (4.6 3 50 mm,
3 mm particle size) on a Shimadzu LC2010A system. Amino acid anal-
yses of peptide hydrolysates (6 N HCl, 1% phenol, 155C, 1 hr) were
run on a Beckman 6300 autoanalyzer. MALDI-TOF mass spectra
were recorded on a Voyager DE-STR instrument (Applied Biosys-
tems, Foster City, CA) using a-cyano-4-hydroxy-cinnamic acid as
matrix. Foot-and-mouth disease virus (FMDV) type C-S8c1 was
a plaque-purified derivative of isolate C-S8 (C1-Santapau-Sp/70)
[27]. Monoclonal antibodies have been previously described [12].
Peptide Synthesis
Linear cDnL (n = 1, 2, 3, 4) sequences were prepared as C-terminal
amides following standard Fmoc/tBu protocols on an Applied Bio-
systems 433A peptide synthesizer, starting from 0.1 mmol of
Fmoc-AM-MBHA resin (0.73 mmol/g) and using 10 eq Fmoc-amino
acid, 10 eq 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU)/1-hydroxybenzotriazole (HOBt), and
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82220 eq N,N-diisopropylethylamine for couplings. Peptide resins with
free N terminus were washed with DCM and MeOH and vacuum-
dried prior to acidolysis with reagent R (90% TFA, 2% anisole, 5%
thioanisole, 3% EDT). The crude peptides were purified by prepara-
tive HPLC using linear 10%–35% gradients of acetonitrile in water
(both solvents containing 0.1% TFA) at 25 ml/min. Fractions afford-
ing 98% homogeneity were selected by analytical HPLC using linear
10%–40% acetonitrile (+0.036% TFA) gradients in water (+0.045%
TFA) at 1 ml/min. Further characterization was by MALDI-TOF MS
and amino acid analysis. Global yields were 51% for cD1L, 30%
for cD2L, 15% for cD3L, and 12% for cD4L.
Cyclic peptides were prepared by air oxidation at room tempera-
ture of 30–50 mg lots of the linear precursors under high-dilution
conditions (25 mM peptide) in 0.1 M Tris$HCl, 6 M Gn$HCl, 1 mM
EDTA (pH 8.0) with continuous agitation, and monitored by analytical
HPLC, Ellman’s test, and MALDI-TOF MS. Once completed, reac-
tions were quenched by addition of pure TFA to a final concentration
of 0.5% (pH < 2). Cyclic peptides were purified by preparative HPLC,
with an initial isocratic elution with water (+0.1% TFA) at 15 ml/min
for salt removal, followed by a linear 5%–20% gradient of acetonitrile
(+0.1% TFA) in water (+0.1% TFA) at 25 ml/min. During elution of the
main peptide peak, an isocratic regimen was maintained for better
separation. The final products were further analyzed by HPLC and
MALDI-TOF MS and quantified by amino acid analysis. Global yields
(cyclization and purification) for cD1-cD4 were, respectively, 61%,
35%, 38%, and 22%.
ELISA
Monoclonal and polyclonal antibodies were tested by direct ELISA
for binding to cDn (n = 1, 2, 3, and 4) peptides and their correspond-
ing linear precursors. Controls with inactivated virus were also in-
cluded in the experiment. Microtiter plates (Costar polystyrene,
high binding, Corning, NY) were coated overnight with peptide
(250 ng in 50 ml PBS) or virus (0.5 pmol in 50 ml PBS) at 4C and
then blocked with 100 ml 2% BSA in PBS for 2 hr at 25C. Diluted
antibodies, 50 ml in 1% BSA in PBS, were incubated for 1 hr at
25C; plates were washed three times with 100 ml 0.1% Tween,
0.1% BSA in PBS, goat peroxidase-labeled anti-mouse IgG (Sigma)
was then added at 1/2500 dilution in 0.1% BSA in PBS, and incuba-
tion was carried out for 1 hr, followed by several washing steps and
treatment with H2O2/o-phenylenediamine. After 30 min, the reaction
was stopped by the addition of 50 ml 4 M H2SO4, and absorbance
was measured at 490 nm.
Guinea Pig Immunization and Challenge
Groups of guinea pigs (male Dunkin Hartley Hsd Poc; DH) were inoc-
ulated subcutaneously with each cDn peptide (0.5 mg) in PBS (100
ml) and complete Freund’s adjuvant (100 ml) and boosted intrader-
mally with the same amount of immunogen in PBS and incomplete
Freund’s adjuvant (100 ml each) on days 21 and 42 preimmune
(p.i.). Blood samples were taken at days 0 p.i. and 63 p.i., stored at
4C overnight, and centrifuged at 10,000 rpm and 4C to obtain
the clarified sera. Two animals injected with PBS only were used
as negative controls. Animals were challenged by intradermal injec-
tion in the metatarsal pad of the hind left foot with 106 PFU of VpC-
2C/3A, a guinea pig-adapted type C FMDV [15].
Plaque Reduction in Cell Culture
A plaque reduction assay was carried out on BHK cell monolayers.
Serum serial dilutions were preincubated in duplicate with 150
PFU of FMDV for 90 min at 25C. Aliquots (200 ml) of each sample
were added to p60 Petri plates and incubated for 60 min at 37C.
Cell monolayers were washed with Dulbecco’s modified Eagle’s
medium (DMEM), and agar medium (DMEM, 0.5% agar, 0.1 mg/ml
DEAE-dextran, 1% fetal bovine serum) was added. After 24 hr, cells
were fixed with 10% formaldehyde and stained with crystal violet.
Plaque reduction levels were determined relative to a positive con-
trol (w150 PFU of FMDV, no sera) and corrected for background
signals (plaque reduction of p.i. sera).
STD-NMR
NMR samples were prepared by dissolving 1.25 mg cD2 peptide
(1.38 mM) and when applicable, 2.1 mg of polyclonal antibody mix-
ture (46 mM, Ab/cD2 = 1/30), in 300 ml of phosphate-buffered salinesolution (12 mM phosphate [pH 6.10], 137 mM NaCl, 3 mM KCl,
10% D2O, 0.02% NaN3).
Peptide assignment experiments (1D, TOCSY, and NOESY) were
performed on a Bruker DRX-600 spectrometer at 278 K. A 1D spec-
trum was acquired with 64 scans. TOCSY was acquired using 80 ms
mixing time, with 48 scans and 256 increments. NOESY was ac-
quired with 300 ms mixing time, 128 scans, and 256 increments.
STD-NMR spectra were acquired at 500 MHz and 278 K on a Varian
Inova VXR-500. Saturation frequencies were set at 21 ppm (on-res-
onance) and 215 ppm (off-resonance) using a series of Gaussian
pulses of excitation width 50 Hz, with 5 ms delay between pulses,
for a total saturation time of 2.5 s. Water suppression was achieved
by WATERGATE. Protein was eliminated with a 20 ms spin lock.
Subtraction of saturated spectra (on-resonance) from reference
spectra (off-resonance) was performed by phase cycling after every
scan. A total of 8K scans was acquired for sensitivity in the differ-
ence experiment. Subtraction control was performed accumulating
8K scans, with equal saturation frequencies on- and off-resonance
at d –1 ppm.
Supplemental Data
Supplemental Data including cyclization conditions for cD peptides
(Table S1), antibody titers of peptide-immunized guinea pigs (Table
S2), and NMR assignment of cD2 peptide (Table S3) may be found at
http://www.chembiol.com/cgi/content/full/13/8/815/DC1/.
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